6. Panda A, Garg I, Truty MJ, et al. Borderline Resectable and Locally Advanced Pancreas Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Neoadjuvant Therapy Pathologic Response and Prediction of Survival. AJR Am J Roentgenol. 2020 Oct 21. Available at: https://www.ajronline.org/doi/pdf/10.2214/AJR.20.24567.
Subscribe Now
Manage Subscription
facebook.svglinkedin.svgtwitter X.svg
contact usprivacy policyterms & conditions
© 2023 GE HealthCare. GE is a trademark of the General Electric Company used under trademark license.
previous arrow_PURPLE.svgnext arrow_PURPLE.svg

PET/MR biomarkers guide personalized treatment for patients with pancreatic cancer

Researchers from the Mayo Clinic have found that PET/MR can help guide post- neoadjuvant therapy (NAT) pancreatic cancer treatment decisions to optimize treatment decisions and long-term outcomes6. The study, recently published in the American Journal of Roentgenology, assessed pathologic tumor response to emergent pancreatic cancer therapies and predicted overall survival using PET/MR and CT data.
The authors wrote that PET/MR provides a non-invasive selection tool to help clinicians decide if surgery will benefit the patient, and if alternate treatment regimens could optimize a patient’s chances for favorable long-term outcomes. They concluded that PET/ MR’s potential in pancreatic cancer provides clinicians with a clearer picture of the therapies’ efficacy and can guide next steps, potentially allowing specialists to tailor care to each patient’s disease profile.